Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 switch study of picankibart versus continued IL-17 inhibitor therapy in plaque psoriasis with inadequate response to prior IL-17 biologic treatment
CTR20251862Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of picankibart in plaque psoriasis, sponsored by InnoCare Pharma. Started May 2025; status: active.
02
Drugs
picankibart
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20251862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251862.